<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PEN</journal-id>
<journal-id journal-id-type="hwp">sppen</journal-id>
<journal-id journal-id-type="nlm-ta">JPEN J Parenter Enteral Nutr</journal-id>
<journal-title>Journal of Parenteral and Enteral Nutrition</journal-title>
<issn pub-type="ppub">0148-6071</issn>
<issn pub-type="epub">1941-2444</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0148607112449650</article-id>
<article-id pub-id-type="publisher-id">10.1177_0148607112449650</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Tutorial</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A Tutorial on Fatty Acid Biology</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Kalish</surname><given-names>Brian T.</given-names></name>
<xref ref-type="aff" rid="aff1-0148607112449650">1</xref>
<xref ref-type="aff" rid="aff2-0148607112449650">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fallon</surname><given-names>Erica M.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0148607112449650">1</xref>
<xref ref-type="aff" rid="aff2-0148607112449650">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Puder</surname><given-names>Mark</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0148607112449650">1</xref>
<xref ref-type="aff" rid="aff2-0148607112449650">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0148607112449650"><label>1</label>Department of Surgery, Boston Children’s Hospital, Boston, Massachusetts</aff>
<aff id="aff2-0148607112449650"><label>2</label>The Vascular Biology Program, Harvard Medical School, Boston, Massachusetts</aff>
<author-notes>
<corresp id="corresp1-0148607112449650">Mark Puder, MD, PhD, Boston Children’s Hospital, 300 Longwood Ave, Fegan Building 3rd Floor, Boston, MA 02115; e-mail: <email>Mark.puder@childrens.harvard.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2012</year>
</pub-date>
<volume>36</volume>
<issue>4</issue>
<fpage>380</fpage>
<lpage>388</lpage>
<history>
<date date-type="received">
<day>10</day>
<month>4</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>4</day>
<month>5</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p>Fatty acids are an extraordinarily diverse set of molecules that serve as sources of fuel, key components of cell structure, and parent molecules for bioactive second messengers. The metabolism of fatty acids is part of a delicate homeostasis that is fundamental to normal functioning and the response to pathophysiologic insult. The growing body of evidence on nutrition demonstrates that we truly “are what we eat,” and the fatty acid content of our diets has far-reaching physiologic implications, many of which we are only beginning to understand. As the gap between basic science and patient care becomes increasingly narrow, clinicians should have a working knowledge of fatty acid biology. This tutorial provides an overview of fatty acid biology with the goal of increasing comfort in discussing how these heterogeneous molecules are classified and metabolized, in addition to how fatty acid content influences basic cellular processes.</p>
</abstract>
<kwd-group>
<kwd>fatty acids</kwd>
<kwd>gastroenterology</kwd>
<kwd>lipids</kwd>
<kwd>ω-3</kwd>
<kwd>ω-6</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Fatty acids are a diverse set of molecules that act as essential cellular building blocks and fuel sources. Early work in this field focused on biochemistry and nutrition, but fatty acids and their derivatives have since been implicated in countless disease states, as well as targeted by numerous therapeutics. Given their pervasive relevance and incorporation within the field of medicine, it is important that clinicians have a working knowledge of fatty acid biology. The purpose of this review is to provide a general background on fatty acid structure, terminology, metabolism, and function.</p>
<sec id="section1-0148607112449650">
<title>Structure</title>
<p>The structure of individual fatty acids determines their biologic function. Fatty acids are hydrophobic (“water-fearing”) molecules composed of a carboxylic acid group and a chain of carbon and hydrogen atoms. <xref ref-type="fig" rid="fig1-0148607112449650">Figure 1A</xref> depicts a prototypical fatty acid with the methyl and carboxyl groups labeled. Fatty acids differ structurally in 4 key ways: (1) the presence and number of double bonds between carbon atoms, (2) the number of carbon atoms, (3) the location of double bonds, and (4) the orientation of the double bond.</p>
<fig id="fig1-0148607112449650" position="float">
<label>Figure 1.</label>
<caption>
<p>(A) Prototypical fatty acid structure, with the methyl and carboxyl group labeled. (B) Unsaturated fatty acids contain double bonds between carbon atoms; the addition of hydrogen atoms to eliminate double bonds creates saturated fatty acids. (C) The orientation of carbon atoms relative to a double bond can be cis (same side of a double bond) or trans (opposite side of a double bond). (D) Skeleton structure of arachidonic acid, with omega (ω) carbon labeled and systematic nomenclature noted.</p>
</caption>
<graphic xlink:href="10.1177_0148607112449650-fig1.tif"/>
</fig>
<p>The type of bond between carbon atoms determines whether the molecule is saturated or unsaturated (<xref ref-type="fig" rid="fig1-0148607112449650">Figure 1B</xref>). Fatty acids are considered saturated if there are no double bonds between any of the carbon atoms. An unsaturated fatty acid can become saturated if the double bond joining the carbon atoms is eliminated with the addition of hydrogen atoms. Fatty acids with a single double bond are termed <italic>monounsaturated fatty acids</italic> (MUFAs), and fatty acids with more than 1 double bond are classified as <italic>polyunsaturated fatty acids</italic> (PUFAs).</p>
<p>Saturated fatty acids can be divided into categories according to the length of the carbon chain: short chain (3–7 carbon atoms), medium chain (8–13 carbon atoms), long chain (14–20 carbon atoms), and very long chain (&gt;21 carbon atoms). Unsaturated fatty acids are typically divided into 3 classes based on the length of the carbon chain: short chain (&lt;19 carbon atoms), long chain (20–24 carbon atoms), and very long chain (&gt;25 carbon atoms).</p>
<p>The terms <italic>cis</italic> and <italic>trans</italic> are used to denote the relative position of the 2 carbon atoms connected to a double bond (<xref ref-type="fig" rid="fig1-0148607112449650">Figure 1C</xref>). Atoms are cis if they lie on the same side of the double bond, and atoms are trans if they lie on the opposite side of the double bond. Nearly all naturally occurring unsaturated fatty acids are cis, with the double bond most commonly in the third, sixth, or ninth position from the terminal methyl group. Most trans fatty acids are derived from hydrogenation, a manufacturing process used to stabilize oils from oxidation.</p>
<p>The degree of saturation alters the melting point of the fatty acids. Unsaturated fatty acids have a lower melting point than saturated fatty acids, due to the double bond(s) that creates a “kink” in the molecule and thereby prevents tight packing as commonly seen with saturated fatty acids. Less thermal energy is required to disrupt these weaker interactions, resulting in the molecules typically assuming a liquid state near room temperature.<sup><xref ref-type="bibr" rid="bibr1-0148607112449650">1</xref></sup></p>
<p>Fatty acids are the fundamental building blocks of more structurally complex lipids, including esters, triglycerides, phospholipids, and glycolipids. An ester molecule is formed in the reaction between a carboxylic acid and an alcohol. Three fatty acids in an ester linkage combined with a glycerol form a triacylglycerol, or commonly termed a <italic>triglyceride</italic> (<xref ref-type="fig" rid="fig2-0148607112449650">Figure 2A</xref>). Phospholipids, the components of the lipid bilayer of cell membranes (<xref ref-type="fig" rid="fig2-0148607112449650">Figure 2B</xref>), are divided into glycerophospholipids (phosphoglycerides) and sphingolipids. The former is composed of a hydrophobic backbone of a glycerol and fatty acids linked through a phosphodiester bond to a polar head group of a phosphate and an alcohol. The latter is composed of a backbone of sphingosine and a fatty acid linked with a sugar. A glycolipid, another membrane lipid, similarly has a sphingosine backbone, but the polar group is a sugar.</p>
<fig id="fig2-0148607112449650" position="float">
<label>Figure 2.</label>
<caption><p>(A) A triglyceride is composed of 3 fatty acids joined by a glycerol backbone. (B) Schematic of the phospholipid bilayer composition of a cell membrane. (C) Schematic of a chylomicron, which is a lipoprotein particle that transports dietary lipids from the intestine.</p></caption>
<graphic xlink:href="10.1177_0148607112449650-fig2.tif"/>
</fig>
</sec>
<sec id="section2-0148607112449650">
<title>Nomenclature</title>
<p>Several systems of nomenclature are used to identify fatty acids. The systematic name is defined according to the International Union of Pure and Applied Chemists (IUPAC). This system is based on the number of carbon atoms and the position of double bonds, if any. The carbons are numbered starting with the carboxyl group, and the double bond is identified by the lower number of the 2 carbons it joins. The systematic name for α-linolenic acid, for example, is cis,cis,cis-9,12,15-octadecatrienoic acid.</p>
<p>The systematic IUPAC terminology is often burdensome, and therefore, common or “trivial” names are used. Shorthand notation of fatty acids is denoted in a “C:D (n minus)” format, where C is the number of carbon atoms, D is the number of double bonds, and “n minus” denotes the position of the closest double bond relative to the terminal methyl group. For example, α-linolenic acid is abbreviated 18:3(n-3). The n is often replaced with ω (omega), and therefore, the terms <italic>ω-3</italic> and <italic>ω-6</italic> indicate that, from the methyl end, the double bond begins at the third and sixth carbons, respectively. Saturated fatty acids are often denoted in shorthand in the format C:0, where the zero reflects the absence of double bonds. For example, palmitic acid is written as 16:0 (16 carbon atoms, 0 double bonds). Finally, the delta (Δ) classification system is based on the number of carbon atoms between the carbon in the carboxyl group and the nearest double bond; the orientation of the carbons around the double bond (cis/trans) is also noted. For example, the notation for α-linolenic acid would be cis-Δ9, cis-Δ12, cis-Δ15-18:3. <xref ref-type="table" rid="table1-0148607112449650">Table 1</xref> lists examples of nomenclature for selected clinically relevant fatty acids. <xref ref-type="fig" rid="fig1-0148607112449650">Figure 1D</xref> depicts the nomenclature and structure of arachidonic acid (AA). The carbons preceding the double bonds are labeled to correspond with the systematic nomenclature. The structure is depicted as a carbon “skeleton” in which each inflection point denotes a carbon atom.</p>
<table-wrap id="table1-0148607112449650" position="float">
<label>Table 1.</label>
<caption><p>Nomenclature of Selected Clinically Relevant Fatty Acids</p></caption>
<graphic alternate-form-of="table1-0148607112449650" xlink:href="10.1177_0148607112449650-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="center"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Common Name</th>
<th align="center">IUPAC (Systematic) Name</th>
<th align="center">Δ<sup>x</sup> Name</th>
<th align="center">C:D Name</th>
<th align="center"><italic>n</italic>-x Name</th>
<th align="center">Dietary Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palmitoleic acid</td>
<td>(Z)-hexadec-9-enoic acid</td>
<td>cis-Δ<sup>9</sup></td>
<td>16:1</td>
<td>n-7</td>
<td>Marine oils, macadamia oil</td>
</tr>
<tr>
<td>Oleic acid (OA)</td>
<td>(Z)-octadec-9-enoic acid</td>
<td>cis-Δ<sup>9</sup></td>
<td>18:1</td>
<td>n-9</td>
<td>Olive and canola oil; high-oleic sunflower and safflower oils</td>
</tr>
<tr>
<td>Linoleic acid (LA)</td>
<td>(9Z,12Z)-octadeca-9,12-dienoic acid</td>
<td>cis-Δ<sup>9</sup>, cis-Δ<sup>12</sup></td>
<td>18:2</td>
<td>n-6</td>
<td>Vegetable oils</td>
</tr>
<tr>
<td>α-Linolenic acid (ALA)</td>
<td>(9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid</td>
<td>cis,cis,cis-Δ<sup>9</sup>,Δ<sup>12</sup>,Δ<sup>15</sup></td>
<td>18:3</td>
<td>n-3</td>
<td>Flaxseed, perilla, and canola oils</td>
</tr>
<tr>
<td>Arachidonic acid (AA)</td>
<td>(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid</td>
<td>cis,cis,cis,cis-Δ<sup>5</sup>,Δ<sup>8</sup>, Δ<sup>11</sup>,Δ<sup>14</sup></td>
<td>20:4</td>
<td>n-6</td>
<td>Animal fats, egg lipids, liver</td>
</tr>
<tr>
<td>Eicosapentaenoic acid (EPA)</td>
<td>(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid</td>
<td>cis,cis,cis,cis,cis-Δ<sup>5</sup>,Δ<sup>8</sup>,Δ<sup>11</sup>,Δ<sup>14</sup>,Δ<sup>17</sup></td>
<td>20:5</td>
<td>n-3</td>
<td>“Oily” fish (eg, salmon, herring, anchovy, mackerel)</td>
</tr>
<tr>
<td>Docosahexaenoic acid (DHA)</td>
<td>(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid</td>
<td>cis,cis,cis,cis,cis,cis- Δ<sup>4</sup>,Δ<sup>7</sup>,Δ<sup>10</sup>,Δ<sup>13</sup>, Δ<sup>16</sup>,Δ<sup>19</sup></td>
<td>22:6</td>
<td>n-3</td>
<td>“Oily” fish (eg, salmon, herring, anchovy, mackerel)</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section3-0148607112449650">
<title>PUFA Metabolism</title>
<p>There are 3 families of PUFAs: (1) ω-3, derived from α-linolenic acid (ALA, 18:3n-3); (2) ω-6, derived from linoleic acid (LA, 18:2n-6); and (3) ω-9, derived from oleic acid (OA, 18:1n-9).</p>
<p>PUFAs are metabolized within a biochemical pathway through a series of desaturation and elongation steps (<xref ref-type="fig" rid="fig3-0148607112449650">Figure 3</xref>). In humans, there are 3 desaturase enzymes: Δ<sup>5</sup>, Δ<sup>6</sup>, and Δ<sup>9</sup>. These enzymes function to insert double bonds at the fifth, sixth, and ninth carbon atoms in a fatty acid chain, respectively. LA is metabolized by the Δ<sup>6</sup> to γ-linolenic acid (GLA), which is then elongated to form dihomo-γ-linolenic acid (DGLA). DGLA is converted to AA, the most biologically relevant molecule in the ω-6 pathway, via the Δ<sup>5</sup> desaturase enzyme. ALA is processed by the same enzymes to its biologically relevant metabolites: eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3). ALA is converted to EPA after Δ<sup>6</sup> desaturation, elongation, and Δ<sup>5</sup> desaturation. EPA is transformed through several intermediates (via elongation, desaturation, and β-oxidation) to form DHA. DHA can be retroconverted, or converted back to EPA, as well. Finally, in the ω-9 pathway, OA undergoes desaturation, elongation, and further desaturation to form mead acid (MA; eicosatrienoic acid, 20:3n-9).</p>
<fig id="fig3-0148607112449650" position="float">
<label>Figure 3.</label>
<caption>
<p>The 3 main families of polyunsaturated fatty acids (ω-3, ω-6, and ω-9) are metabolized primarily through desaturation and elongation to from physiologically relevant downstream molecules, including docosahexaenoic acid, eicosapentaenoic acid, arachidonic acid, and mead acid. Of note, α-linolenic acid and linoleic acid are considered the classical essential fatty acids.</p>
</caption>
<graphic xlink:href="10.1177_0148607112449650-fig3.tif"/>
</fig>
<p>Of the 3 families of PUFAs, only OA can be synthesized de novo in humans. Humans lack the necessary desaturase enzymes to insert double bonds at positions-3 and -6, and therefore, ALA and LA must be acquired from the diet.<sup><xref ref-type="bibr" rid="bibr2-0148607112449650">2</xref></sup> An increase in dietary consumption of LA or ALA above the amount required by the human body is not associated with a relative increase in the membrane phospholipid levels of LA or ALA. Desaturation of LA and ALA, therefore, may be regulated by the needs of membrane recycling rather than dietary intake. In addition, the conversion of ALA to DHA is highly inefficient such that increased dietary intake of ALA does not lead to higher tissue levels of DHA, although it may lead to higher tissue levels of EPA.<sup>3-6</sup> The overall rate of conversion of ALA to EPA and DHA has been reported as 0.2% and 0.05%, respectively.<sup><xref ref-type="bibr" rid="bibr7-0148607112449650">7</xref></sup> However, increased dietary intake of DHA or EPA is associated with relative increases in the membrane phospholipid levels of these fatty acids. DHA and EPA inhibit the desaturation of LA to AA, and therefore, an increase in membrane levels of DHA and EPA is associated with a decrease in membrane levels of AA. This has important ramifications for cell signaling, especially in the context of inflammation, as will be discussed later.</p>
<p>ALA, LA, and OA all compete for the same Δ<sup>5</sup> and Δ<sup>6</sup> desaturases and elongases, with the enzymes showing a preference in the order of ω-3 &gt; ω-6 &gt; ω-9. Therefore, under normal conditions, very little OA is metabolized to MA (<xref ref-type="fig" rid="fig3-0148607112449650">Figure 3</xref>). An increase in the concentration of MA indicates that there is little ALA and LA as a substrate for desaturation, and the production of MA is a compensatory mechanism to maintain the same number of double bonds in membrane-bound fatty acids. Essential fatty acid deficiency (EFAD) is defined by the relative decrease in AA levels and increase in MA levels. Structurally, AA, a tetraene, contains 4 double bonds, whereas MA, a triene, contains 3 double bonds, so the ratio of MA to AA is often referred to as the triene-tetraene ratio. A triene-tetraene ratio &gt;0.2 biochemically defines EFAD, with clinical symptoms (eg, dermatitis, alopecia, coagulopathy, impaired growth) typically manifested when the ratio exceeds 0.4.<sup><xref ref-type="bibr" rid="bibr8-0148607112449650">8</xref>,<xref ref-type="bibr" rid="bibr9-0148607112449650">9</xref></sup></p>
<p>All downstream fatty acids can be synthesized from LA and ALA. For these reasons, ALA and LA are classically considered the “essential fatty acids.” Burr and Burr<sup><xref ref-type="bibr" rid="bibr10-0148607112449650">10</xref></sup> were the first to describe the “essentiality” of ALA and LA in 1929, when they demonstrated that AA and ALA alone could reverse symptoms of EFAD in rats fed a fat-free diet. However, other fatty acids—notably AA, DHA, and EPA—are necessary for normal development and function throughout the life cycle and are hence referred to as “conditionally essential fatty acids.” There is emerging evidence from animal studies that the supplementation of DHA and AA alone—without ALA and LA—is sufficient to prevent EFAD.<sup><xref ref-type="bibr" rid="bibr11-0148607112449650">11</xref></sup> Research has shown that EFAD can develop when less than 1%–2% of total calories are provided by ALA and LA. Premature infants, in particular, have a higher requirement for ALA and LA due to their limited fat stores and hence require at least 3% of calories from essential fatty acids.<sup><xref ref-type="bibr" rid="bibr12-0148607112449650">12</xref></sup></p>
</sec>
<sec id="section4-0148607112449650">
<title>Physiologic Functions of Fatty Acids</title>
<p>Fatty acids serve 3 basic biologic functions: (1) sources of fuel, in the form of uncharged esters with glycerol called triacylglycerols; (2) components of cell membranes, in the form of phospholipids and glycolipids; and (3) second messengers.</p>
<sec id="section5-0148607112449650">
<title>Fuel</title>
<p>Fats as sources of fuel are derived from 3 sources: the diet, storage depots, and exportation from one organ to another. Triglycerides from the enteral diet are emulsified by bile salts to form micelles in the intestine. Pancreatic lipases cleave the triacyglycerols into free fatty acids and 2-monoacylglycerols. These are incorporated into micelles, along with unesterified cholesterol and fat-soluble vitamins (A, D, E, and K). These components are smaller and can therefore diffuse across the intestinal epithelium, where they are reassembled to triacyglycerols and incorporated into lipoprotein molecules called chylomicrons (<xref ref-type="fig" rid="fig2-0148607112449650">Figure 2C</xref>). Chylomicrons enter the lymphatic system, then the blood, and are finally transported to muscle and adipose tissue. Endothelial lipoprotein lipase digests the triglycerides within chylomicrons to fatty acids and glycerol, which can be absorbed into the cell and either oxidized for energy or stored as triacyglycerols.</p>
<p>Gastrointestinal hormones (eg, epinephrine and glucagon) signal the need for metabolic energy and the mobilization of fat from intracellular stores. Once mobilized, fatty acids are transported to tissues, where they undergo degradation in the form of β-oxidation. Long-chain fatty acids must undergo a carnitine-mediated, 3-step process to move from the cytosol to the mitochondria where β-oxidation occurs. During this process, 2-carbon units of acetyl-CoA are successively removed from the carboxyl end of the fatty acid chain. This degradation occurs in 4 steps: dehydrogenation to introduce a double bond, hydration to introduce oxygen, dehydrogenation of the alcohol to a ketone, and cleavage by coenzyme A. Acetyl-CoA then enters the citric acid cycle in the mitrochondrial matrix, where it is oxidized to water and carbon dioxide. The electrons extracted from fatty acids enter the electron transport chain to generate energy, or adenosine triphosphate (ATP). The oxidative yield of 1 g of fatty acid is 9 kilocalories (kcal), as compared with 4 kcal from protein or carbohydrates. Fatty acids have a greater energy yield because of their reduced and nearly anhydrous form.</p>
<p>Fatty acid synthesis is most active in the liver and the lactating mammary gland. Malonyl-CoA is the donor of the 2-carbon units, and formation of malonyl-CoA by the carboxylation of acetyl-CoA is the rate-limiting step of fatty acid synthesis. Fatty acids are synthesized in a stepwise fashion with the sequential addition of 2-carbon units. Fatty acid synthase catalyzes a 7-step cycle to add 2-carbon units to the growing fatty acid chain until palmitate, C16:0, is typically produced. Palmitate may be elongated to form other long-chain fatty acids or alternatively desaturated to form MUFAs.</p>
<p>PUFAs exert powerful effects on the genes that regulate fatty acid metabolism. The net effect of this influence is to shift metabolism toward fatty acid oxidation and away from de novo lipogenesis and lipid storage. PUFAs regulate at least 4 families of transcription factors that influence fatty acid synthesis and oxidation, as well as cholesterol and bile acid metabolism: peroxisome proliferator-activated receptor (PPAR; α, β, and γ), liver X receptors (LXRs; α and β), hepatic nuclear factor-4 (HNF-4) α, and sterol regulatory element binding proteins (SREBPs) 1 and 2.<sup><xref ref-type="bibr" rid="bibr13-0148607112449650">13</xref></sup> PUFAs activate PPARs, thereby promoting fatty acid oxidation, whereas PUFAs also antagonize SREBPs and LXRs, thereby inhibiting de novo lipogenesis. In addition, PUFAs inhibit transcription of the leptin gene; decreased leptin levels are associated with decreased adiposity.</p>
</sec>
<sec id="section6-0148607112449650">
<title>Cell Membranes</title>
<p>Fatty acid–derived phospholipids and glycolipids are the primary constituents of the lipid bilayer of cell membranes (<xref ref-type="fig" rid="fig2-0148607112449650">Figure 2A</xref>). After adipose tissue, the brain has the second highest level of lipid in the body, and most of this lipid is membrane bound.<sup><xref ref-type="bibr" rid="bibr14-0148607112449650">14</xref></sup> AA and DHA, in particular, are found in high concentration in excitable membranes of the brain and retina. Large quantities of DHA and AA are deposited in the brain during central nervous system development, and therefore, dietary deficiencies of these fatty acids are associated with impaired neurodevelopment.<sup><xref ref-type="bibr" rid="bibr15-0148607112449650">15</xref><xref ref-type="bibr" rid="bibr16-0148607112449650"/><xref ref-type="bibr" rid="bibr17-0148607112449650"/>-<xref ref-type="bibr" rid="bibr18-0148607112449650">18</xref></sup></p>
<p>Fatty acid structure modulates membrane fluidity and the behavior of membrane-bound receptors. Higher saturated fatty acid content decreases membrane fluidity, whereas higher unsaturated fatty acid content increases fluidity. Membrane fluidity has a direct impact on the number and affinity of cell surface receptors. For instance, membranes with lower unsaturated fatty acid content (more rigid) show a reduction in insulin receptors, which may contribute to insulin resistance.<sup><xref ref-type="bibr" rid="bibr19-0148607112449650">19</xref></sup></p>
</sec>
<sec id="section7-0148607112449650">
<title>Second Messengers</title>
<p>Membrane-bound PUFAs serve as the precursors to a variety of second messengers. These lipid mediators are both pro- and anti-inflammatory, and therefore, the physiologic state can vary dramatically depending on this equilibrium. Eicosanoids are a class of signaling molecules derived from 20-carbon PUFAs (the term <italic>eicosanoids</italic> comes from the Greek word for “twenty,” <italic>eikosi</italic>) that actively regulate a variety of biologic functions, including host defense, vasoactivity, and reproduction.<sup><xref ref-type="bibr" rid="bibr20-0148607112449650">20</xref></sup> The eicosanoids have receptors on diverse cell types throughout the body, and therefore, they exert control over a broad array of physiologic functions. Classically, 4 classes of eicosanoids—prostaglandins, prostacyclins, thromboxanes, and leukotrienes—act locally through G-protein-coupled receptors. Prostaglandins regulate cellular growth and smooth muscle tone, along with pain sensitization, thrombus formation, parturition, and cellular growth.<sup><xref ref-type="bibr" rid="bibr21-0148607112449650">21</xref></sup> Prostacyclins inhibit platelet aggregation and promote vasodilation, whereas thromboxanes promote hemostasis through platelet aggregation. Leukotrienes act as potent chemotactic agents for inflammatory cells, induce bronchoconstriction, and increase vascular permeability.<sup><xref ref-type="bibr" rid="bibr22-0148607112449650">22</xref></sup></p>
<p>Eicosanoids are not stored in cells; rather, they are synthesized in response to extracellular stimuli, such as growth factors and hormones. Phospholipase A<sub>2</sub> (PLA<sub>2</sub>) is an enzyme that releases 20-carbon PUFAs from the middle carbon of glycerol. Due to the relative excess of AA in the cell membrane compared with other PUFAs such as DHA and EPA, AA is the primary substrate for eicosanoid synthesis. There are 3 key pathways in eicosanoid production: cyclooxygenase, lipoxygenase, and cytochrome P450 (<xref ref-type="fig" rid="fig4-0148607112449650">Figure 4</xref>). Each of these will be reviewed below.</p>
<fig id="fig4-0148607112449650" position="float">
<label>Figure 4.</label>
<caption><p>Eiconsaoids are signaling molecules derived from 20-carbon precursors. This schematic outlines the 3 pathways for formation of eicosanoids: cyclooxygenase, lipoxygenase, and cytochrome P450.</p></caption>
<graphic xlink:href="10.1177_0148607112449650-fig4.tif"/>
</fig>
<p>The cyclooxygenase (COX) pathway is responsible for the production of the “prostanoids”: prostaglandins, prostacyclins, and thromboxanes. COX metabolizes AA, EPA, and DGLA to produce the 2-series prostaglandins and thromboxanes, the 3-series prostaglandins and thromboxanes, and the 1-series prostaglandins, respectively. There are 2 main enzymes in the human COX pathway: COX-1 and COX-2. The traditional teaching is that the COX-1 enzyme is constitutively expressed throughout the body, whereas COX-2 is inducible under inflammatory stress. However, recent evidence suggests that expression of both enzymes is present under both normal and pathologic conditions.<sup><xref ref-type="bibr" rid="bibr23-0148607112449650">23</xref></sup> Classical nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both enzymes, thereby decreasing prostaglandin and thromboxane synthesis, which in turn has an anti-inflammatory, antipyretic, antithrombotic, and analgesic effect. However, classical NSAIDs may cause gastrointestinal complications because the inhibition of COX-1 specifically decreases the production of prostaglandins that are protective in the gastric mucosa. Selective COX-2 inhibitors that preserve the production of physiologic prostaglandins in the stomach have reduced gastrointestinal side effects.<sup><xref ref-type="bibr" rid="bibr24-0148607112449650">24</xref></sup></p>
<p>The lipoxygenase pathway produces leukotrienes and lipoxins. Lipoxins are nonclassical eicosanoids that are potent anti-inflammatory mediators and act as counterregulators of leukocyte trafficking.<sup><xref ref-type="bibr" rid="bibr25-0148607112449650">25</xref></sup> To date, 2 lipoxins have been identified: lipoxin A<sub>4</sub> and lipoxin B<sub>4</sub>. At least 6 lipoxygenase enzymes produce leukotrienes and lipoxins; many of these enzymes have been implicated in the pathogenesis of cardiovascular disease, cancer, rheumatologic conditions, and allergy.<sup><xref ref-type="bibr" rid="bibr22-0148607112449650">22</xref></sup> The first 2 steps in leukotriene synthesis are catalyzed by 5-lipoxygenase (5-LO). 12/15-Lipoxygenase (12/15-LO) is highly expressed in eosinophils and in the airway epithelium, and it has been studied extensively in the setting of atherosclerosis.<sup><xref ref-type="bibr" rid="bibr26-0148607112449650">26</xref>,<xref ref-type="bibr" rid="bibr27-0148607112449650">27</xref></sup> 12/15-LO is also responsible for the production of lipoxins. Lipoxins are synthesized through 15-lipoxygenase (15-LO), which converts AA to 15-hydroxyeicosatetraenoic acid (15-HETE); 15-HETE is further processed by 5-lipoxygenase and other epoxide hydrolases.</p>
<p>The cytochrome P450 pathway—the third pathway in AA metabolism—has 2 components: ω-hydroxylases which convert AA to hydroxyeicosatetraenoic acids (HETEs), and epoxygenases, which convert AA to epoxyeicosatrienoic acids (EETs). The HETEs are proinflammatory and proangiogenic and are known to regulate vascular tone. The EETs are anti-inflammatory, vasodilatory, and proangiogenic and have thus generated significant interest in the fields of cardiovascular and oncologic medicine.<sup><xref ref-type="bibr" rid="bibr28-0148607112449650">28</xref>,<xref ref-type="bibr" rid="bibr29-0148607112449650">29</xref></sup></p>
<p>The beneficial effects of ω-3 fatty acids are suggested to occur due to suppression of the production of AA-derived prostaglandins and leukotrienes. As stated previously, ω-3-derived PUFAs competitively inhibit the desaturation of LA to AA.<sup><xref ref-type="bibr" rid="bibr30-0148607112449650">30</xref>,<xref ref-type="bibr" rid="bibr31-0148607112449650">31</xref></sup> Increased intake of DHA and EPA raises the level of these ω-3 fatty acids in inflammatory cells and decreases the amount of AA available for eicosanoid synthesis.<sup><xref ref-type="bibr" rid="bibr32-0148607112449650">32</xref>,<xref ref-type="bibr" rid="bibr33-0148607112449650">33</xref></sup> Furthermore, DGLA and EPA can compete with AA for access to COX and lipoxygenase, therefore limiting AA-derived eicosanoid synthesis. More recently, the paradigm for understanding the anti-inflammatory effects of ω-3 fatty acids has shifted with the discovery of a novel class of lipid molecules termed <italic>specialized pro-resolving mediators</italic>. These molecules are short-lived endogenous mediators of cellular programs to restore tissue homeostasis and resolve inflammation. This novel class includes the lipoxins, as previously described, as well as lipid autocoids derived from ω-3 fatty acids: resolvins, protectins, and maresins (<xref ref-type="fig" rid="fig5-0148607112449650">Figure 5</xref>). DHA gives rise to the D-series resolvins and protectins, as well as maresins, whereas EPA gives rise to the E-series resolvins. These molecules have protective effects in a variety of animal models of inflammatory disease, including colitis, ischemia-reperfusion, pain, sepsis, and acute lung injury.<sup><xref ref-type="bibr" rid="bibr34-0148607112449650">34</xref><xref ref-type="bibr" rid="bibr35-0148607112449650"/><xref ref-type="bibr" rid="bibr36-0148607112449650"/>-<xref ref-type="bibr" rid="bibr37-0148607112449650">37</xref></sup></p>
<fig id="fig5-0148607112449650" position="float">
<label>Figure 5.</label>
<caption><p>Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) serve as parent molecules in the formation of specialized pro-resolving mediators that serve to actively reduce cellular inflammation. LOX, lipoxygenase.</p></caption>
<graphic xlink:href="10.1177_0148607112449650-fig5.tif"/>
</fig>
</sec>
</sec>
<sec id="section8-0148607112449650">
<title>Free Fatty Acid Receptors</title>
<p>Recently, a number of G-protein-coupled receptors (GPRs) for free fatty acids have been identified. FFAR2 (free fatty acid receptor; GPR43) and FFAR3 (GPR41) are both receptors for short-chain fatty acids.<sup><xref ref-type="bibr" rid="bibr38-0148607112449650">38</xref>,<xref ref-type="bibr" rid="bibr39-0148607112449650">39</xref></sup> FFAR1 (GPR40) is a receptor for medium- and long-chain fatty acids, particularly in pancreatic β cells and enteroendocrine cells. Activation of FFAR1 enhances glucose-stimulated insulin release, and FFAR1 knockout mice have been shown to be resistant to hyperglycemia, hepatic steatosis, and obesity-induced hyperinsulinemia.<sup><xref ref-type="bibr" rid="bibr40-0148607112449650">40</xref></sup> GPR120 functions as an ω-3 fatty acid receptor/sensor in proinflammatory macrophages and mature adipocytes. The activation of this receptor by DHA leads to the inhibition of tumor necrosis factor–α (TNF-α), Toll-like receptor 4 (TLR-4), and lipopolysaccharide (LPS)–mediated inflammatory cascades. GPR120 expression has been found to be higher in adipose tissue of obese individuals than in lean controls.<sup><xref ref-type="bibr" rid="bibr41-0148607112449650">41</xref></sup> In addition, a mutation that inhibits GPR120 signaling has been shown to increase the risk of obesity in European populations.<sup><xref ref-type="bibr" rid="bibr41-0148607112449650">41</xref></sup> Because of the roles these molecules play in energy homeostasis, there is significant interest in pharmacologically targeting both GPR40 and GPR120.</p>
</sec>
<sec id="section9-0148607112449650">
<title>Conclusions</title>
<p>The world of fatty acid biology is incredibly complex. There is an ever-expanding literature on the role of fatty acids in maintaining nutrition homeostasis, driving and resolving inflammation, and influencing the risk and severity of diseases ranging from atherosclerosis to schizophrenia to cancer. The physiologic effects of altering the consumption and metabolism of fatty acids are only beginning to be unraveled, and the fundamentals of fatty acid biology will be critical to translating these advancements.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: none declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0148607112449650">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ratnayake</surname><given-names>WM</given-names></name>
<name><surname>Galli</surname><given-names>C</given-names></name>
</person-group>. <article-title>Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: a background review paper</article-title>. <source>Ann Nutr Metab</source>. <year>2009</year>;<volume>55</volume>(<issue>1-3</issue>):<fpage>8</fpage>-<lpage>43</lpage>.</citation>
</ref>
<ref id="bibr2-0148607112449650">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Innis</surname><given-names>SM</given-names></name>
</person-group>. <article-title>Essential fatty acid requirements in human nutrition</article-title>. <source>Can J Physiol Pharmacol</source>. <year>1993</year>;<volume>71</volume>(<issue>9</issue>):<fpage>699</fpage>-<lpage>706</lpage>.</citation>
</ref>
<ref id="bibr3-0148607112449650">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mantzioris</surname><given-names>E</given-names></name>
<name><surname>James</surname><given-names>MJ</given-names></name>
<name><surname>Gibson</surname><given-names>RA</given-names></name>
<name><surname>Cleland</surname><given-names>LG</given-names></name>
</person-group>. <article-title>Dietary substitution with an alpha-linolenic acid-rich vegetable oil increases eicosapentaenoic acid concentrations in tissues</article-title>. <source>Am J Clin Nutr</source>. <year>1994</year>;<volume>59</volume>(<issue>6</issue>):<fpage>1304</fpage>-<lpage>1309</lpage>.</citation>
</ref>
<ref id="bibr4-0148607112449650">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Burdge</surname><given-names>GC</given-names></name>
<name><surname>Calder</surname><given-names>PC</given-names></name>
</person-group>. <article-title>Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults</article-title>. <source>Reprod Nutr Dev</source>. <year>2005</year>;<volume>45</volume>(<issue>5</issue>):<fpage>581</fpage>-<lpage>597</lpage>.</citation>
</ref>
<ref id="bibr5-0148607112449650">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gerster</surname><given-names>H</given-names></name>
</person-group>. <article-title>Can adults adequately convert alpha-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3)?</article-title> <source>Int J Vitam Nutr Res</source>. <year>1998</year>;<volume>68</volume>(<issue>3</issue>):<fpage>159</fpage>-<lpage>173</lpage>.</citation>
</ref>
<ref id="bibr6-0148607112449650">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Francois</surname><given-names>CA</given-names></name>
<name><surname>Connor</surname><given-names>SL</given-names></name>
<name><surname>Bolewicz</surname><given-names>LC</given-names></name>
<name><surname>Connor</surname><given-names>WE</given-names></name>
</person-group>. <article-title>Supplementing lactating women with flaxseed oil does not increase docosahexaenoic acid in their milk</article-title>. <source>Am J Clin Nutr</source>. <year>2003</year>;<volume>77</volume>(<issue>1</issue>):<fpage>226</fpage>-<lpage>233</lpage>.</citation>
</ref>
<ref id="bibr7-0148607112449650">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pawlosky</surname><given-names>RJ</given-names></name>
<name><surname>Hibbeln</surname><given-names>JR</given-names></name>
<name><surname>Novotny</surname><given-names>JA</given-names></name>
<name><surname>Salem</surname><given-names>N</given-names><suffix>Jr</suffix></name>
</person-group>. <article-title>Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans</article-title>. <source>J Lipid Res</source>. <year>2001</year>;<volume>42</volume>(<issue>8</issue>):<fpage>1257</fpage>-<lpage>1265</lpage>.</citation>
</ref>
<ref id="bibr8-0148607112449650">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mascioli</surname><given-names>EA</given-names></name>
<name><surname>Lopes</surname><given-names>SM</given-names></name>
<name><surname>Champagne</surname><given-names>C</given-names></name>
<name><surname>Driscoll</surname><given-names>DF</given-names></name>
</person-group>. <article-title>Essential fatty acid deficiency and home total parenteral nutrition patients</article-title>. <source>Nutrition</source>. <year>1996</year>;<volume>12</volume>(<issue>4</issue>):<fpage>245</fpage>-<lpage>249</lpage>.</citation>
</ref>
<ref id="bibr9-0148607112449650">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alfin-Slater</surname><given-names>RB</given-names></name>
<name><surname>Aftergood</surname><given-names>L</given-names></name>
</person-group>. <article-title>Essential fatty acids reinvestigated</article-title>. <source>Physiol Rev</source>. <year>1968</year>;<volume>48</volume>(<issue>4</issue>):<fpage>758</fpage>-<lpage>784</lpage>.</citation>
</ref>
<ref id="bibr10-0148607112449650">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Burr</surname><given-names>GO</given-names></name>
<name><surname>Burr</surname><given-names>MM</given-names></name>
</person-group>. <article-title>Nutrition classics from <italic>The Journal of Biological Chemistry</italic></article-title> <volume>82</volume>:<fpage>345</fpage>-<lpage>67</lpage>, <comment>1929. A new deficiency disease produced by the rigid exclusion of fat from the diet. <italic>Nutr Rev</italic>. 1973;31(8):248-249</comment>.</citation>
</ref>
<ref id="bibr11-0148607112449650">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Le</surname><given-names>HD</given-names></name>
<name><surname>Meisel</surname><given-names>JA</given-names></name>
<name><surname>de Meijer</surname><given-names>VE</given-names></name>
<etal/>
</person-group>. <article-title>Docosahexaenoic acid and arachidonic acid prevent essential fatty acid deficiency and hepatic steatosis</article-title> [<comment>published online ahead of print October 30, 2011</comment>]. <source>JPEN J Parenter Enteral Nutr</source>. doi:10.1177/0148607111414580<pub-id pub-id-type="doi">10.1177/0148607111414580</pub-id>.</citation>
</ref>
<ref id="bibr12-0148607112449650">
<label>12.</label>
<citation citation-type="book">
<collab>American Academy of Pediatrics</collab>. <source>Pediatric Nutrition Handbook</source>. <edition>6th ed.</edition> <publisher-loc>Elk Grove Village, IL</publisher-loc>: <publisher-name>American Academy of Pediatrics</publisher-name>; <year>2009</year>.</citation>
</ref>
<ref id="bibr13-0148607112449650">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jump</surname><given-names>DB</given-names></name>
</person-group>. <article-title>Dietary polyunsaturated fatty acids and regulation of gene transcription</article-title>. <source>Curr Opin Lipidol</source>. <year>2002</year>;<volume>13</volume>(<issue>2</issue>):<fpage>155</fpage>-<lpage>164</lpage>.</citation>
</ref>
<ref id="bibr14-0148607112449650">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sastry</surname><given-names>PS</given-names></name>
</person-group>. <article-title>Lipids of nervous tissue: composition and metabolism</article-title>. <source>Prog Lipid Res</source>. <year>1985</year>;<volume>24</volume>(<issue>2</issue>):<fpage>69</fpage>-<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr15-0148607112449650">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Georgieff</surname><given-names>MK</given-names></name>
<name><surname>Innis</surname><given-names>SM</given-names></name>
</person-group>. <article-title>Controversial nutrients that potentially affect preterm neurodevelopment: essential fatty acids and iron</article-title>. <source>Pediatr Res</source>. <year>2005</year>;<volume>57</volume>(<issue>5, pt 2</issue>):<fpage>99R</fpage>-<lpage>103R</lpage>.</citation>
</ref>
<ref id="bibr16-0148607112449650">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Innis</surname><given-names>SM</given-names></name>
</person-group>. <article-title>Essential fatty acids in growth and development</article-title>. <source>Prog Lipid Res</source>. <year>1991</year>;<volume>30</volume>(<issue>1</issue>):<fpage>39</fpage>-<lpage>103</lpage>.</citation>
</ref>
<ref id="bibr17-0148607112449650">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bourre</surname><given-names>JM</given-names></name>
<name><surname>Francois</surname><given-names>M</given-names></name>
<name><surname>Youyou</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>The effects of dietary alpha-linolenic acid on the composition of nerve membranes, enzymatic activity, amplitude of electrophysiological parameters, resistance to poisons and performance of learning tasks in rats</article-title>. <source>J Nutr</source>. <year>1989</year>;<volume>119</volume>(<issue>12</issue>):<fpage>1880</fpage>-<lpage>1892</lpage>.</citation>
</ref>
<ref id="bibr18-0148607112449650">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yamamoto</surname><given-names>N</given-names></name>
<name><surname>Saitoh</surname><given-names>M</given-names></name>
<name><surname>Moriuchi</surname><given-names>A</given-names></name>
<name><surname>Nomura</surname><given-names>M</given-names></name>
<name><surname>Okuyama</surname><given-names>H</given-names></name>
</person-group>. <article-title>Effect of dietary alpha-linolenate/linoleate balance on brain lipid compositions and learning ability of rats</article-title>. <source>J Lipid Res</source>. <year>1987</year>;<volume>28</volume>(<issue>2</issue>):<fpage>144</fpage>-<lpage>151</lpage>.</citation>
</ref>
<ref id="bibr19-0148607112449650">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Das</surname><given-names>UN</given-names></name>
</person-group>. <article-title>A defect in the activity of Delta6 and Delta5 desaturases may be a factor predisposing to the development of insulin resistance syndrome</article-title>. <source>Prostaglandins Leukot Essent Fatty Acids</source>. <year>2005</year>;<volume>72</volume>(<issue>5</issue>):<fpage>343</fpage>-<lpage>350</lpage>.</citation>
</ref>
<ref id="bibr20-0148607112449650">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Funk</surname><given-names>CD</given-names></name>
</person-group>. <article-title>Prostaglandins and leukotrienes: advances in eicosanoid biology</article-title>. <source>Science</source>. <year>2001</year>;<volume>294</volume>(<issue>5548</issue>):<fpage>1871</fpage>-<lpage>1875</lpage>.</citation>
</ref>
<ref id="bibr21-0148607112449650">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harizi</surname><given-names>H</given-names></name>
<name><surname>Corcuff</surname><given-names>JB</given-names></name>
<name><surname>Gualde</surname><given-names>N</given-names></name>
</person-group>. <article-title>Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology</article-title>. <source>Trends Mol Med</source>. <year>2008</year>;<volume>14</volume>(<issue>10</issue>):<fpage>461</fpage>-<lpage>469</lpage>.</citation>
</ref>
<ref id="bibr22-0148607112449650">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haeggstrom</surname><given-names>JZ</given-names></name>
<name><surname>Funk</surname><given-names>CD</given-names></name>
</person-group>. <article-title>Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease</article-title>. <source>Chem Rev</source>. <year>2011</year>;<volume>111</volume>(<issue>10</issue>): <fpage>5866</fpage>-<lpage>5898</lpage>.</citation>
</ref>
<ref id="bibr23-0148607112449650">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zidar</surname><given-names>N</given-names></name>
<name><surname>Odar</surname><given-names>K</given-names></name>
<name><surname>Glavac</surname><given-names>D</given-names></name>
<name><surname>Jerse</surname><given-names>M</given-names></name>
<name><surname>Zupanc</surname><given-names>T</given-names></name>
<name><surname>Stajer</surname><given-names>D</given-names></name>
</person-group>. <article-title>Cyclooxygenase in normal human tissues—is COX-1 really a constitutive isoform, and COX-2 an inducible isoform?</article-title> <source>J Cell Mol Med</source>. <year>2009</year>;<volume>13</volume>(<issue>9B</issue>): <fpage>3753</fpage>-<lpage>3763</lpage>.</citation>
</ref>
<ref id="bibr24-0148607112449650">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hooper</surname><given-names>L</given-names></name>
<name><surname>Brown</surname><given-names>TJ</given-names></name>
<name><surname>Elliott</surname><given-names>R</given-names></name>
<name><surname>Payne</surname><given-names>K</given-names></name>
<name><surname>Roberts</surname><given-names>C</given-names></name>
<name><surname>Symmons</surname><given-names>D</given-names></name>
</person-group>. <article-title>The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review</article-title>. <source>BMJ</source>. <year>2004</year>;<volume>329</volume>(<issue>7472</issue>):<fpage>948</fpage>.</citation>
</ref>
<ref id="bibr25-0148607112449650">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Serhan</surname><given-names>CN</given-names></name>
</person-group>. <article-title>Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution</article-title>. <source>Prostaglandins Leukot Essent Fatty Acids</source>. <year>2005</year>;<volume>73</volume>(<issue>3-4</issue>):<fpage>141</fpage>-<lpage>162</lpage>.</citation>
</ref>
<ref id="bibr26-0148607112449650">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nadel</surname><given-names>JA</given-names></name>
<name><surname>Conrad</surname><given-names>DJ</given-names></name>
<name><surname>Ueki</surname><given-names>IF</given-names></name>
<name><surname>Schuster</surname><given-names>A</given-names></name>
<name><surname>Sigal</surname><given-names>E</given-names></name>
</person-group>. <article-title>Immunocytochemical localization of arachidonate 15-lipoxygenase in erythrocytes, leukocytes, and airway cells</article-title>. <source>J Clin Invest</source>. <year>1991</year>;<volume>87</volume>(<issue>4</issue>):<fpage>1139</fpage>-<lpage>1145</lpage>.</citation>
</ref>
<ref id="bibr27-0148607112449650">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>L</given-names></name>
<name><surname>Funk</surname><given-names>CD</given-names></name>
</person-group>. <article-title>Lipoxygenase pathways in atherogenesis</article-title>. <source>Trends Cardiovasc Med</source>. <year>2004</year>;<volume>14</volume>(<issue>5</issue>):<fpage>191</fpage>-<lpage>195</lpage>.</citation>
</ref>
<ref id="bibr28-0148607112449650">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Panigrahy</surname><given-names>D</given-names></name>
<name><surname>Edin</surname><given-names>ML</given-names></name>
<name><surname>Lee</surname><given-names>CR</given-names></name>
<etal/>
</person-group>. <article-title>Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice</article-title>. <source>J Clin Invest</source>. <year>2012</year>;<volume>122</volume>(<issue>1</issue>):<fpage>178</fpage>-<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr29-0148607112449650">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Imig</surname><given-names>JD</given-names></name>
</person-group>. <article-title>Epoxides and soluble epoxide hydrolase in cardiovascular physiology</article-title>. <source>Physiol Rev</source>. <year>2012</year>;<volume>92</volume>(<issue>1</issue>):<fpage>101</fpage>-<lpage>130</lpage>.</citation>
</ref>
<ref id="bibr30-0148607112449650">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Emken</surname><given-names>EA</given-names></name>
<name><surname>Adlof</surname><given-names>RO</given-names></name>
<name><surname>Duval</surname><given-names>SM</given-names></name>
<name><surname>Nelson</surname><given-names>GJ</given-names></name>
</person-group>. <article-title>Effect of dietary docosahexaenoic acid on desaturation and uptake in vivo of isotope-labeled oleic, linoleic, and linolenic acids by male subjects</article-title>. <source>Lipids</source>. <year>1999</year>;<volume>34</volume>(<issue>8</issue>):<fpage>785</fpage>-<lpage>791</lpage>.</citation>
</ref>
<ref id="bibr31-0148607112449650">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nassar</surname><given-names>BA</given-names></name>
<name><surname>Huang</surname><given-names>YS</given-names></name>
<name><surname>Manku</surname><given-names>MS</given-names></name>
<name><surname>Das</surname><given-names>UN</given-names></name>
<name><surname>Morse</surname><given-names>N</given-names></name>
<name><surname>Horrobin</surname><given-names>DF</given-names></name>
</person-group>. <article-title>The influence of dietary manipulation with n-3 and n-6 fatty acids on liver and plasma phospholipid fatty acids in rats</article-title>. <source>Lipids</source>. <year>1986</year>;<volume>21</volume>(<issue>10</issue>):<fpage>652</fpage>-<lpage>656</lpage>.</citation>
</ref>
<ref id="bibr32-0148607112449650">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Calder</surname><given-names>PC</given-names></name>
<name><surname>Yaqoob</surname><given-names>P</given-names></name>
<name><surname>Thies</surname><given-names>F</given-names></name>
<name><surname>Wallace</surname><given-names>FA</given-names></name>
<name><surname>Miles</surname><given-names>EA</given-names></name>
</person-group>. <article-title>Fatty acids and lymphocyte functions</article-title>. <source>Br J Nutr</source>. <year>2002</year>;<volume>87</volume>(<issue>suppl 1</issue>):<fpage>S31</fpage>-<lpage>S48</lpage>.</citation>
</ref>
<ref id="bibr33-0148607112449650">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Calder</surname><given-names>PC</given-names></name>
</person-group>. <article-title>Polyunsaturated fatty acids and inflammation</article-title>. <source>Prostaglandins Leukot Essent Fatty Acids</source>. <year>2006</year>;<volume>75</volume>(<issue>3</issue>):<fpage>197</fpage>-<lpage>202</lpage>.</citation>
</ref>
<ref id="bibr34-0148607112449650">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arita</surname><given-names>M</given-names></name>
<name><surname>Yoshida</surname><given-names>M</given-names></name>
<name><surname>Hong</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid–induced colitis</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2005</year>;<volume>102</volume>(<issue>21</issue>):<fpage>7671</fpage>-<lpage>7676</lpage>.</citation>
</ref>
<ref id="bibr35-0148607112449650">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Duffield</surname><given-names>JS</given-names></name>
<name><surname>Hong</surname><given-names>S</given-names></name>
<name><surname>Vaidya</surname><given-names>VS</given-names></name>
<etal/>
</person-group>. <article-title>Resolvin D series and protectin D1 mitigate acute kidney injury</article-title>. <source>J Immunol</source>. <year>2006</year>;<volume>177</volume>(<issue>9</issue>):<fpage>5902</fpage>-<lpage>5911</lpage>.</citation>
</ref>
<ref id="bibr36-0148607112449650">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huang</surname><given-names>L</given-names></name>
<name><surname>Wang</surname><given-names>CF</given-names></name>
<name><surname>Serhan</surname><given-names>CN</given-names></name>
<name><surname>Strichartz</surname><given-names>G</given-names></name>
</person-group>. <article-title>Enduring prevention and transient reduction of postoperative pain by intrathecal resolvin D1</article-title>. <source>Pain</source>. <year>2011</year>;<volume>152</volume>(<issue>3</issue>):<fpage>557</fpage>-<lpage>565</lpage>.</citation>
</ref>
<ref id="bibr37-0148607112449650">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>B</given-names></name>
<name><surname>Gong</surname><given-names>X</given-names></name>
<name><surname>Wan</surname><given-names>JY</given-names></name>
<etal/>
</person-group>. <article-title>Resolvin D1 protects mice from LPS-induced acute lung injury</article-title>. <source>Pulm Pharmacol Ther</source>. <year>2011</year>;<volume>24</volume>(<issue>4</issue>):<fpage>434</fpage>-<lpage>441</lpage>.</citation>
</ref>
<ref id="bibr38-0148607112449650">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brown</surname><given-names>AJ</given-names></name>
<name><surname>Goldsworthy</surname><given-names>SM</given-names></name>
<name><surname>Barnes</surname><given-names>AA</given-names></name>
<etal/>
</person-group>. <article-title>The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids</article-title>. <source>J Biol Chem</source>. <year>2003</year>;<volume>278</volume>(<issue>13</issue>):<fpage>11312</fpage>-<lpage>11319</lpage>.</citation>
</ref>
<ref id="bibr39-0148607112449650">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Le Poul</surname><given-names>E</given-names></name>
<name><surname>Loison</surname><given-names>C</given-names></name>
<name><surname>Struyf</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation</article-title>. <source>J Biol Chem</source>. <year>2003</year>;<volume>278</volume>(<issue>28</issue>):<fpage>25481</fpage>-<lpage>25489</lpage>.</citation>
</ref>
<ref id="bibr40-0148607112449650">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Itoh</surname><given-names>Y</given-names></name>
<name><surname>Kawamata</surname><given-names>Y</given-names></name>
<name><surname>Harada</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40</article-title>. <source>Nature</source>. <year>2003</year>;<volume>422</volume>(<issue>6928</issue>):<fpage>173</fpage>-<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr41-0148607112449650">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ichimura</surname><given-names>A</given-names></name>
<name><surname>Hirasawa</surname><given-names>A</given-names></name>
<name><surname>Poulain-Godefroy</surname><given-names>O</given-names></name>
<etal/>
</person-group>. <article-title>Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human</article-title>. <source>Nature</source>. <year>2012</year>;<volume>483</volume>:<fpage>350</fpage>-<lpage>354</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>